Efficacy of TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

ABSTRACT:

Background

Transarterial chemoembolization (TACE) is currently widely used in the treatment of patients with unresectable hepatocellular carcinoma. However, the combination of TACE with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) during treatment remains controversial. This study aims to evaluate the efficacy and safety of TACE combined with TKIs and ICIs in patients with unresectable hepatocellular carcinoma and to compare this approach with other treatment regimens.

Method

We conducted a systematic search of relevant studies from multiple online databases, with the search deadline set at March 2025. We explored the relationship between prognosis and adverse reactions of TACE + TKIs + ICIs combination therapy, TACE + TKIs therapy, and TACE mono

SUBMITTER: Ye K 

PROVIDER: S-EPMC12739551 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature